#Tcelltherapy

2 months ago

Autologous T cell therapy targeting multiple antigens shows promise treating pancreatic cancer – BioNews Central A recent study reports that a new immunotherapy using autologous T cell therapy targeting multiple tumor antigens has shown promising safety and clinical effects in a first-in-human phase 1/2 trial for pancreatic cancer. ...

A recent study reports that a new #immunotherapy using autologous #TCellTherapy targeting multiple #TumorAntigens has shown promising safety and clinical effects in a first-in-human phase 1/2 #ClinicalTrial for #PancreaticCancer.
#PancreaticCancerTreatment

1 0 0 0

Celiac.com

@celiac-com.bsky.social

2 months ago

https://youtu.be/8wB
#CeliacDisease #DietaryHealth #ScienceNews #GlutenFree #TCellTherapy #Immunology #AutoimmuneDisease #MedicalBreakthrough #HealthResearch #Nutrition

0 0 0 0

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

2 months ago

Personalized T cell therapy shows potential for targeting stable regions of HIV and enhancing immune control.
#HIV #TCellTherapy #ConservedEpitopes #Immunotherapy #HIVResearch
www.nature.com/articles/s41...

0 0 0 0

HuMOLYTE

@humolyte.bsky.social

4 months ago

A Common Virus Just Got a Lot More Dangerous

A new study reveals that a common strain of HPV can directly cause skin cancer by hijacking our cells—and that fixing the immune system can stop it.

#CancerResearch #HPV #SkinCancerAwareness #Immunotherapy #TCellTherapy

0 0 0 0

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

4 months ago

Targeting #SRSF1 with TN2008 disrupts tumor cell metabolism and enhances CD8+ T cell #AntiTumorImmunity, improving glycolytic reprogramming, effector function, and adoptive #TCellTherapy efficacy. @fudan-university.bsky.social #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

2 0 0 0

Department of Biomedicine🔬🧪

@biomedizin.unibas.ch

5 months ago

© Martin Oeggerli (www.Micronaut.ch) 2019-2025, with Marcel Philipp Trefny, and Prof. Alfred Zippelius, Cancer Immunology, University Hospital Basel, Pathology University Hospital Basel, and C-CINA, Biozentrum, University Basel

Researchers @biomedizin.unibas.ch developed cartilage implants from nasal septum cells, and showed that allowing them to mature for two weeks improved outcomes. 🔬Congratulations to all contributors.
doi.org/10.1126/scit...

#Immunotherapy #CancerImmunology #FusionProtein #PD1IL2v #TCellTherapy

2 0 0 0

@arxivlens.bsky.social

7 months ago

Conserved programs and specificities of T cells targeting hematological malignancies
Abelin, J. G., Boschert, T. et al.
Paper
Details
#TCellTherapy #HematologicalMalignancies #CancerImmunology

0 0 0 0

Nanolive

@nanolive-sa.bsky.social

7 months ago

How do antibodies affect T–cell–target interactions?
With the LIVE T Cell Assay, you can track these effects live:
🟡Immune synapse formation
🔴T cell behavior
🔵Target cell fate
See how your candidates perform in real time, no dyes, no disruption
Watch here: bit.ly/3Ue6JrJ
#TCellTherapy #LiveCellTech

0 0 0 0

Nanolive

@nanolive-sa.bsky.social

7 months ago

Which CAR-T clone works best?
Don’t rely on endpoints.
Our LIVE T Cell Assay shows real-time, label-free killing efficiency with digital overlays:
🟢 green = healthy
🟠 orange = dead
🎥 Watch 4 clones tested on the same cancer line: bit.ly/40vBvQp
#TCellTherapy #LiveCellImaging #CAR-T

0 0 0 0

Nanolive

@nanolive-sa.bsky.social

7 months ago

Liquid models need a new lens—and we’ve got it. Nanolive’s LIVE T Cell Assay captures how T cells behave in suspension: real time, no dyes.
🎥 Watch them in action: bit.ly/40vBvQp
#TCellTherapy #LiquidTumors #ImmunoOncology

0 0 0 0

The Journal of Rheumatology

@jrheumatol.bsky.social

9 months ago

Review Article

Role of CD19 Chimeric Antigen Receptor T Cell Therapy in Idiopathic Inflammatory Myopathies

📖 www.jrheum.org/cgi/content/...

#TCellTherapy #inflammatorymyopathies

1 0 0 0

MSK Library

@msklibrary.bsky.social

10 months ago

Featured today by @MSKLibrary: Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific dx.doi.org/10.1016/j.xc...

#CancerImmunotherapy #TumorMicroenvironment
#ImmunoOncology #TCellTherapy #Tebentafusp #CD3Engager #ImmuneLandscape #Cancer

1 0 0 0

Stanford Cancer Institute

@stanford-cancer.bsky.social

11 months ago

Stanford infuses first patient with innovative solid tumor therapy Stanford treated its first patient with Tecelra, a breakthrough engineered T cell receptor therapy that uses a patient’s own immune cells to target cancer.

Stanford has treated its 1st patient with Tecelra. Tecelra is the first FDA-approved engineered TCR therapy, specifically for #SynovialSarcoma. med.stanford.edu/cancer/about... @drbetofmdphd.bsky.social #Tcelltherapy

1 0 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

11 months ago

Orca Bio’s T-cell therapy shows promise in haematological malignancies - PharmaTimes The company is preparing to submit the results to the FDA this year

#OrcaBio #allogeneiccelltherapy #OrcaT #Tcelltherapy #investigationalallogeneicTcellimmunotherapy #PrecisionTtrial #acutemyeloidleukaemia #acutelymphoblasticleukaemia #highriskmyelodysplasticsyndrome #mixedphenotypeacuteleukaemia #alloHSCT #cGvHD #alloHSCT
pharmatimes.com/news/orca-bi...

0 0 0 0

Sylvain Simon

@sylvainsimon.bsky.social

11 months ago

With these advances, we hope to see the Bi-ChTCRs move to the clinic, hoping to generate long-lasting responses and prevent relapses in patients.
@fredhutch.bsky.social @natureportfolio.nature.com @naturecancer.bsky.social
#CancerResearch #Immunotherapy #TCellTherapy #BiChTCR #SyntheticImmunity

3 0 0 0

Sylvain Simon

@sylvainsimon.bsky.social

11 months ago

With these advances, we hope to see the Bi-ChTCRs move to the clinic, hoping to generate long-lasting responses and prevent relapses in cancer patients.

@fredhutch.bsky.social
#CancerResearch #Immunotherapy #TCellTherapy #Bi-ChTCR #SyntheticImmunity

0 0 0 0

Katie Chapple

@katiechapple.bsky.social

1 year ago

Swarm Oncology announces Martin Olin as Chief Executive Officer - Swarm Oncology Swarm Oncology Unveils Highly Differentiated, Personalised T Cell Therapy Platform to Significantly Improve Treatment Outcome for Cancer Patients and Appoints Martin Olin as Chief Executive Officer

Officially launched (a few weeks ago)! It has been an exciting time working on this novel T cell therapy project for the past year with the aim to address a significant unmet need in solid cancer treatments #tcelltherapy #cancerresearch
swarmoncology.bio/swarm-oncolo...

1 0 0 0